Early growth responsive gene 3 in human breast carcinoma: A regulator of estrogen-meditated invasion and a potent prognostic factor

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 279-292

  Suzuki, Takashi ^a   Inoue, Akio ^b,d   Miki, Yasuhiro ^a   Moriya, Takuya ^a   Akahira, Jun Ichi ^a   Ishida, Takanori ^a   Hirakawa, Hisashi ^c   Yamaguchi, Yuri ^b   Hayashi, Shin Ichi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c TOHOKU ROSAI HOSPITAL   (Japan)

^d InfoGenes Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; EARLY GROWTH RESPONSE FACTOR 3; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL LINE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; NUDE MOUSE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECURRENT DISEASE; RISK FACTOR; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELLS, CULTURED; EARLY GROWTH RESPONSE PROTEIN 3; ESTROGENS; FEMALE; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROGNOSIS; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 34547806636     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0005     Document Type: Article

References (35)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM & McEwan RN 1987 A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Research 47 3239-3245.
2. Berstein LM, Wang JP, Zheng H, Yue W, Conaway M & Santen RJ 2004 Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical Cancer Research 10 1530-1534.
3. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH & Mader S 2004 Genome-wide identification of high-affinity estrogen response elements in human and mouse. Molecular Endocrinology 18 1411-1427.
4. Chan CM, Martin LA, Johnston SR, Ali S & Dowsett M 2002 Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology 81 333-341.
5. Dumoulin FL, Nischalke HD, Leifeld L, von dem Bussche A, Rockstroh JK, Sauerbruch T & Spengler U 2000 Semiquantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. Journal of Immunological Methods 241 109-119.
6. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19 403-410.
7. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B & Senn HJ 2005 Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Annals of Oncology 16 1569-1583.
8. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N & Yamaguchi Y 2003 The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocrine-Related Cancer 10 193-202.
9. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R & Hayashi S 2002 Development of cDNA microarray for expression profiling of estrogen-responsive genes. Journal of Molecular Endocrinology 29 175-192.
10. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R & Hayashi SI 2004 Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. Journal of Molecular Endocrinology 32 649-661.
11. Jouvert P, Dietrich JB, Aunis D & Zwiller J 2002 Differential rat brain expression of EGR proteins and of the transcriptional corepressor NAB in response to acute or chronic cocaine administration. Neuromolecular Medicine 1 137-151.
12. Korach KS 1994 Insights from the study of animals lacking functional estrogen receptor. Science 266 1524-1527.
13. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468.
14. Mercier G, Turque N & Schumacher M 2001 Early activation of transcription factor expression in Schwann cells by progesterone. Brain Research. Molecular Brain Research 97 137-148.
15. O'Donovan KJ, Wilkens EP & Baraban JM 1998 Sequential expression of Egr-1 and Egr-3 in hippocampal granule cells following electroconvulsive stimulation. Journal of Neurochemistry 70 1241-1248.
16. O'Donovan KJ, Tourtellotte WG, Millbrandt J & Baraban JM 1999 The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends in Neurosciences 22 167-173.
17. Paik S, Hartmann DP, Dickson RB & Lippman ME 1994 Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Research and Treatment 31 301-307.
18. Patwardhan S, Gashler A, Siegel MG, Chang LC, Joseph LJ, Shows TB, Le Beau MM & Sukhatme VP 1991 EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. Oncogene 6 917-928.
19. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M et al. 2005 Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24 4531-4539.
20. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W & Shim WS 2001 Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 79 115-125.
21. Santen RJ, Song RX, Zhang Z, Yue W & Kumar R 2004 Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clinical Cancer Research 10 337S-345S.
22. Steeg PS & Zhou Q 1998 Cyclins and breast cancer. Breast Cancer Research and Treatment 52 17-28.
23. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N & Sasano H 2005a Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer 12 701-720.
24. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T, Muramatsu M, Ouchi Y, Sasano H & Inoue S 20056 Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clinical Cancer Research 11 6148-6154.
25. Taniguchi S, Tatsuka M, Nakamatsu K, Inoue M, Sadano H, Okazaki H, Iwamoto H & Baba T 1989 High invasiveness associated with augmentation of motility in a fos-transferred highly metastatic rat 3Y1 cell line. Cancer Research 49 6738-6744.
26. Thomas DB 1984 Do hormones cause cancer? Cancer 53 595-604.
27. Tourtellotte WG & Milbrandt J 1998 Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3. Nature Genetics 20 87-91.
28. Tourtellotte WG, Keller-Peck C, Milbrandt J & Kucera J 2001 The transcription factor Egr3 modulates sensory axon-myotube interactions during muscle spindle morphogenesis. Developmental Biology 232 388-399.
29. Tsai MJ & O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486.
30. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y & Inoue S 2002 Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417 871-875.
31. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A & Speleman F 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3 research0034.1-11.
32. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R & Cohen PA 2005 Molecular changes associated with the agonist activity of hydroxytamoxifen and the hyper-response to estradiol in hydroxytamoxifen-resistant breast cancer cell lines. Endocrine-Related Cancer 12 75-92.
33. Vihko R & Apter D 1989 Endogenous steroids in the pathophysiology of breast cancer. CRC Critical Reviews in Oncology/Hematology 9 1-16.
34. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J & Lupu R 2000 Expression an d regulation of estrogen receptor beta in human breast tumors and cell lines. Oncology Reports 7 157-167.
35. Xi H & Kersh GJ 2004 Early growth response gene 3 regulates thymocyte proliferation during the transition from CD4-CD8- to CD4+CD8+. Journal of Immunology 172 964-971.